Mycophenolate mofetil
- PDF / 182,047 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 97 Downloads / 137 Views
1 S
Malassezia infection, bacteraemia and pure red cell anaemia: 3 case reports In a study of infants, who underwent living donor liver transplantation, three infants [exact ages and sexes not stated] were described, who developed Malassezia infection (1 patient), bacteraemia (1 patient) and pure red cell anaemia (1 patient) during treatment with mycophenolate mofetil. All three patients underwent living donor liver transplantation. Subsequently, all the patients started receiving oral mycophenolate mofetil twice daily [indications not stated]. An initial dose mycophenolate mofetil was approximately 40 mg/kg/day. Concomitantly, immunosuppression therapy with tacrolimus and unspecified steroids were tapered as per protocol for all the patients. Mycophenolate mofetil doses were gradually increased to reach a mycophenolic acid trough level of 2 mg/mL. However, the patients developed Malassezia infection (n=1), bacteraemia (n=1) and pure red cell anaemia (n=1) secondary to mycophenolate mofetil [durations of treatments to reactions onsets not stated]. Hence, mycophenolate mofetil treatment was stopped for all the patients, which resulted in the improvement of Malassezia infection, bacteraemia and pure red cell anaemia. Ueno T, et al. Serum Trough Concentration and Effects of Mycophenolate Mofetil Based on Pathologic Findings in Infants After Liver Transplantation. Transplantation 803500842 Proceedings 52: 1855-1857, No. 6, Jul-Aug 2020. Available from: URL: http://doi.org/10.1016/j.transproceed.2020.01.160
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
